Dr. Yousuf A. Gaffar, MD

Dr. Gaffar practices at Aah Cypress Denver in Parker, Colorado.

Dr. Gaffar's NPI, 1891798914, was assigned on May 23, 2005. Dr. Gaffar graduated from Saba University School of Medicine in 1998. Dr. Gaffar holds Colorado license CDR.4253.

Dr. Gaffar's primary practice is Aah Cypress Denver, at 9399 Crown Crest Blvd, Parker, CO 80138 in Douglas County. The practice phone is (303) 715-7030.

Dr. Gaffar's primary practice is Aah Cypress Denver in Parker, Colorado. Dr. Gaffar is also affiliated with AdventHealth Parker. The medical group on file is AdventHealth Transplant Institute North Billings. Dmand AI also links Dr. Gaffar to 4 more hospitals, 3 medical groups and 2 group practices and clinics, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gaffar practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Gaffar's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Gaffar is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Gaffar's licenses on file in 6 states: Colorado, Florida, Maryland, Missouri, Pennsylvania and New Jersey.

Dmand AI lists arterial blot clot /embolism, breast cancer, chronic anemia, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), fluid and electrolyte imbalances and immune deficiency disease among the conditions Dr. Gaffar treats.

CMS data shows 13,743 Medicare services from Dr. Gaffar across 18 procedure codes in 2024, for 296 Medicare patients. Medicare paid $105,612 for them. Every service was in an office.

CMS counts 296 Medicare patients who saw Dr. Gaffar in 2024. The largest group is 75 to 84, with 141 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 6% are also on Medicaid. Their average risk score is 2.19, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Gaffar's median patient age at 70, with 52% women.

In 2024, Dr. Gaffar wrote 370 Medicare Part D claims for 112 patients. 68% of them were for generic drugs. CMS names the drug for 127 of them, across 8 drugs with 11 or more claims each, at $202,071 in total drug cost. In 2023, CMS named 563 claims across 25 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 86 out of 100 for Dr. Gaffar for performance year 2024, reported as part of a group. Dr. Gaffar accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Gaffar as offering telehealth.

Dmand AI links 2 papers to Dr. Gaffar in 2015. 2015 was the busiest year, with 2. Dr. Gaffar's most frequent co-authors are Ruben Niesvizky, MD, Billy Wayne Clowney, MD and Ian Winchester Flinn, MD.

Dmand AI links Dr. Gaffar to 5 clinical trials, 2 of them phase 3 studies. 1 is still active or recruiting. Conditions studied include Breast Neoplasms, Carcinoma, Non-Small-Cell Lung and Colonic Neoplasms.

CMS Open Payments shows 1,539 general payments to Dr. Gaffar from 65 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 62% of the total. Rigel Pharmaceuticals, Inc. paid the most, $265,727. It also lists 1 research payment totaling $2,075 in 2019.

Dmand AI lists 2 awards for Dr. Gaffar, most recently Castle Connolly Top Doctor in 2024. Dr. Gaffar serves on US Oncology GI Oncology Research Committee and US Oncology Thoracic Oncology Committee.

Dr. Gaffar graduated from Saba University School of Medicine in 1998. Dr. Gaffar is a member of ASCO.

Dr. Gaffar is in network with 11 carriers, including Aetna, Blue Cross Blue Shield of Michigan and CareFirst BlueCross BlueShield. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.